Lidia Kletchikova Brown, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brown’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A97089 · Current
Licensed to practise in California · since 2006 · expires 2028-05-31 · Saint Petersburg State I.P. Pavlov Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 036117540Licensed Physician And Surgeon · since 2007 · expires 2014-07-31Not RenewedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$64,736
Medicare paid this office $64,736 for 259 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 123 | $21,622 | $176 |
| Botox | 14 | $20,117 | None |
| Return visit (30+ min) | 47 | $5,006 | $91 |
| Long return visit (40+ min) | 25 | $3,972 | $153 |
| New patient visit (45+ min) | 28 | $3,540 | $126 |
See all 8 services
| New patient visit (60+ min) | 123 | $21,622 | $176 |
| Botox | 14 | $20,117 | None |
| Return visit (30+ min) | 47 | $5,006 | $91 |
| Long return visit (40+ min) | 25 | $3,972 | $153 |
| New patient visit (45+ min) | 28 | $3,540 | $126 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 13 | $2,689 | $128 |
| Nerve test | 11 | $1,599 | $145 |
| Short return visit (20+ min) | 11 | $582 | $53 |
Who their Medicare patients are
259 Original Medicare patients in 2024. Average age 75 · Women 61% · Also on Medicaid 13% · Health risk score 1.10. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 66% · Depression 28% · Diabetes 22% · Coronary heart disease 20% · Atrial fibrillation 19% · Cancer 17% · Chronic kidney disease 16% · Stroke 15% · COPD 13% · Heart failure 11% · Dementia 11%.
The office billed $255,238, Medicare allowed $89,415 and paid $64,736; for 4,599 services of 26 kinds; $20,122 of it was for drugs given in the office and $44,614 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 259 | 4,599 | 75 | 1.10 | $255,238 | $64,736 |
| 2023 | 260 | 2,645 | 76 | 1.17 | $254,165 | $68,239 |
| 2022 | 278 | 3,427 | 79 | 1.19 | $332,483 | $99,295 |
| 2021 | 296 | 2,281 | 77 | 1.23 | $362,948 | $102,427 |
| 2020 | 227 | 3,921 | 79 | 1.27 | $293,027 | $77,026 |
| 2019 | 264 | 5,437 | 77 | 1.54 | $358,320 | $92,508 |
| 2018 | 238 | 5,842 | 78 | 1.34 | $314,213 | $79,372 |
| 2017 | 232 | 4,630 | 77 | 1.43 | $265,123 | $66,207 |
| 2016 | 230 | 430 | 77 | 1.51 | $84,913 | $42,832 |
| 2015 | 209 | 454 | 78 | 1.68 | $78,627 | $43,770 |
| 2014 | 197 | 407 | 79 | 1.42 | $78,318 | $41,480 |
| 2013 | 239 | 551 | 78 | 1.55 | $75,853 | $52,062 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| New patient visit (60+ min) | 83 | $16,068 | $194 |
| Return visit (30+ min) | 88 | $13,084 | $111 |
| Long return visit (40+ min) | 49 | $7,765 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,878 | $157 |
| New patient visit (45+ min) | 19 | $2,757 | $145 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 19 | $2,394 | $92 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $2,196 | $110 |
2022: 9 services
| Return visit (30+ min) | 117 | $20,951 | $117 |
| New patient visit (60+ min) | 86 | $17,112 | $199 |
| Long return visit (40+ min) | 78 | $15,551 | $167 |
| Telephone medical discussion with physician, 21-30 minutes | 52 | $9,723 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,801 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,407 | $92 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 24 | $2,541 | $91 |
| New patient visit (60+ min) | 14 | $2,310 | $165 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 17 | $1,519 | $80 |
2021: 15 services
| Return visit (30+ min) | 114 | $23,235 | $116 |
| New patient visit (60+ min) | 81 | $15,940 | $197 |
| Long return visit (40+ min) | 72 | $14,827 | $163 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,838 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $5,985 | $92 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 32 | $4,896 | $92 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $3,355 | $124 |
| Short return visit (20+ min) | 33 | $2,690 | $75 |
| New patient visit (60+ min) | 12 | $2,021 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,756 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,719 | $123 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 21 | $1,716 | $78 |
| New patient visit (45+ min) | 13 | $1,673 | $129 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,143 | $82 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $994 | $90 |
2020: 10 services
| Long return visit (40+ min) | 80 | $13,590 | $124 |
| Return visit (30+ min) | 72 | $11,453 | $101 |
| New patient visit (60+ min) | 58 | $10,660 | $184 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,722 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,334 | $92 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $2,115 | $73 |
| New patient visit (45+ min) | 12 | $1,700 | $142 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 12 | $1,310 | $82 |
| Short return visit (20+ min) | 14 | $1,052 | $70 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $561 | $43 |
2019: 8 services
| Long return visit (40+ min) | 114 | $24,215 | $131 |
| Botox | 12 | $23,375 | None |
| New patient visit (60+ min) | 89 | $16,741 | $188 |
| Return visit (30+ min) | 51 | $5,915 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,086 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,201 | $93 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $3,063 | $128 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 20 | $2,005 | $80 |
2018: 9 services
| Botox | 13 | $25,769 | None |
| Return visit (30+ min) | 89 | $13,070 | $91 |
| New patient visit (60+ min) | 63 | $11,467 | $182 |
| Long return visit (40+ min) | 49 | $6,499 | $123 |
| New patient visit (45+ min) | 44 | $5,961 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,540 | $175 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 13 | $3,367 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,337 | $90 |
| Short return visit (20+ min) | 11 | $636 | $53 |
2017: 6 services
| New patient visit (45+ min) | 82 | $11,275 | $138 |
| Return visit (30+ min) | 78 | $10,551 | $93 |
| Long return visit (40+ min) | 32 | $3,972 | $124 |
| New patient visit (60+ min) | 21 | $3,773 | $180 |
| Short return visit (20+ min) | 33 | $2,818 | $66 |
| New patient visit (30+ min) | 26 | $2,222 | $85 |
2016: 6 services
| Return visit (30+ min) | 91 | $13,534 | $92 |
| New patient visit (45+ min) | 70 | $10,083 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,901 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,408 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,423 | $89 |
| Short return visit | 11 | $664 | $21 |
2015: 9 services
| Return visit (30+ min) | 79 | $13,594 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,139 | $181 |
| New patient visit (45+ min) | 41 | $5,920 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,883 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,564 | $122 |
| New patient visit (30+ min) | 26 | $2,518 | $97 |
| Short return visit (20+ min) | 22 | $1,685 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,115 | $93 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $591 | $35 |
2014: 7 services
| Return visit (30+ min) | 81 | $14,436 | $95 |
| New patient visit (45+ min) | 75 | $10,413 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,955 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,010 | $91 |
| Short return visit (20+ min) | 27 | $1,999 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,499 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,387 | $116 |
2013: 10 services
| Return visit (30+ min) | 87 | $12,662 | $91 |
| New patient visit (45+ min) | 83 | $11,181 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,820 | $166 |
| Short return visit (20+ min) | 43 | $4,081 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $4,025 | $59 |
| New patient visit (60+ min) | 20 | $3,515 | $176 |
| Long return visit (40+ min) | 23 | $3,119 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,129 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,032 | $113 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $1,442 | $32 |
Drugs they prescribed that Part D paid
$39,685
Pharmacies billed $39,685 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 507) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
489 generic and 18 brand-name prescriptions · $39,685 in drug cost · 18 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Memantine | 110 | $4,239 | $39 |
| Carbidopa-Levodopa | 43 | $1,092 | $25 |
| Donepezil Hcl Odt | 38 | $808 | $21 |
| Gabapentin | 42 | $750 | $18 |
| Propranolol | 18 | $481 | $27 |
See all 11 drugs
| Memantine | 110 | $4,239 | $39 |
| Carbidopa-Levodopa | 43 | $1,092 | $25 |
| Donepezil Hcl Odt | 38 | $808 | $21 |
| Gabapentin | 42 | $750 | $18 |
| Propranolol | 18 | $481 | $27 |
| Pregabalin | 22 | $418 | $19 |
| Donepezil | 23 | $320 | $14 |
| Atorvastatin | 18 | $306 | $17 |
| Trazodone | 17 | $204 | $12 |
| Levetiracetam | 13 | $172 | $13 |
| Rizatriptan | 12 | $53 | $4 |
Year by year
| 2024 | 507 | 180 | 0% (0) | 4% | $39,685 |
| 2023 | 844 | 195 | None | None | $132,065 |
| 2022 | 1,051 | 176 | None | None | $151,552 |
| 2021 | 1,086 | 178 | 1% (12) | None | $210,513 |
| 2020 | 755 | 140 | 2% (13) | None | $137,487 |
| 2019 | 587 | 119 | None | None | $86,624 |
| 2018 | 712 | 150 | None | None | $187,677 |
| 2017 | 857 | 163 | None | None | $198,207 |
| 2016 | 872 | 123 | 1% (11) | None | $144,540 |
| 2015 | 670 | 111 | 2% (11) | None | $49,975 |
| 2014 | 706 | 135 | 3% (21) | 15% | $58,962 |
| 2013 | 748 | 132 | 3% (19) | 19% | $67,696 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Nurtec Odt | None | 13 | $30,809 | $2,370 |
| Emgality | Migraine | 11 | $8,262 | $751 |
| Memantine | None | 108 | $7,295 | $68 |
| Rasagiline Mesylate | None | 16 | $5,237 | $327 |
| Pregabalin | None | 41 | $3,965 | $97 |
| Zonisamide | None | 74 | $2,828 | $38 |
| Memantine Hcl Er | None | 12 | $2,715 | $226 |
| Carbidopa-Levodopa | None | 30 | $1,776 | $59 |
| Quetiapine | None | 24 | $1,532 | $64 |
| Lamotrigine | None | 17 | $1,185 | $70 |
| Levetiracetam | None | 28 | $1,112 | $40 |
| Donepezil | None | 37 | $982 | $27 |
| Gabapentin | None | 36 | $860 | $24 |
| Buspirone | None | 34 | $823 | $24 |
| Topiramate | None | 14 | $775 | $55 |
| Duloxetine | None | 18 | $749 | $42 |
| Clonazepam | None | 26 | $734 | $28 |
| Pyridostigmine | None | 13 | $547 | $42 |
| Rizatriptan | None | 13 | $429 | $33 |
| Trazodone | None | 17 | $314 | $18 |
| Sertraline | None | 11 | $274 | $25 |
| Atorvastatin | None | 11 | $114 | $10 |
| Pramipexole Dihydrochloride | None | 11 | $95 | $9 |
| Butalbital-Acetaminophen-Caffe | None | 14 | $36 | $3 |
2022: 25 drugs
| Nurtec Odt | None | 12 | $27,352 | $2,279 |
| Nuedexta | None | 15 | $27,075 | $1,805 |
| Emgality | Migraine | 17 | $12,782 | $752 |
| Memantine | None | 133 | $10,705 | $80 |
| Rasagiline Mesylate | None | 23 | $5,525 | $240 |
| Pregabalin | None | 84 | $4,581 | $55 |
| Carbidopa-Levodopa | None | 37 | $3,116 | $84 |
| Quetiapine | None | 50 | $2,747 | $55 |
| Memantine Hcl Er | None | 15 | $2,556 | $170 |
| Zonisamide | None | 58 | $2,245 | $39 |
| Gabapentin | None | 64 | $1,245 | $19 |
| Clonazepam | None | 20 | $865 | $43 |
| Buspirone | None | 40 | $827 | $21 |
| Lamotrigine | None | 22 | $812 | $37 |
| Levetiracetam | None | 28 | $610 | $22 |
| Donepezil | None | 52 | $596 | $11 |
| Nortriptyline | None | 23 | $377 | $16 |
| Propranolol Hcl Er | None | 13 | $364 | $28 |
| Propranolol | None | 21 | $337 | $16 |
| Rizatriptan | None | 11 | $321 | $29 |
| Topiramate | None | 15 | $268 | $18 |
| Trazodone | None | 22 | $211 | $10 |
| Pramipexole Dihydrochloride | None | 15 | $70 | $5 |
| Fluoxetine | None | 11 | $67 | $6 |
| Butalbital-Acetaminophen-Caffe | None | 15 | $47 | $3 |
2021: 31 drugs
| Nuplazid | Parkinson's psychosis | 13 | $48,088 | $3,699 |
| Nuedexta | None | 28 | $47,844 | $1,709 |
| Rytary | Parkinson's | 14 | $9,376 | $670 |
| Memantine Hcl Er | None | 44 | $8,759 | $199 |
| Eliquis | None | 14 | $7,483 | $534 |
| Memantine | None | 89 | $6,213 | $70 |
| Pregabalin | None | 115 | $5,094 | $44 |
| Carbidopa-Levodopa | None | 63 | $4,119 | $65 |
| Ropinirole Er | None | 20 | $3,909 | $195 |
| Rasagiline Mesylate | None | 11 | $3,169 | $288 |
| Gabapentin | None | 64 | $2,004 | $31 |
| Zonisamide | None | 42 | $1,519 | $36 |
| Sumatriptan | None | 14 | $1,108 | $79 |
| Levetiracetam Er | None | 15 | $1,106 | $74 |
| Clonazepam | None | 28 | $1,004 | $36 |
| Lamotrigine | None | 30 | $900 | $30 |
| Topiramate | None | 20 | $736 | $37 |
| Quetiapine | None | 20 | $697 | $35 |
| Duloxetine | None | 21 | $673 | $32 |
| Fentanyl | None | 11 | $665 | $60 |
| Donepezil | None | 51 | $613 | $12 |
| Ropinirole | None | 18 | $570 | $32 |
| Levetiracetam | None | 13 | $442 | $34 |
| Propranolol | None | 28 | $359 | $13 |
| Buspirone | None | 16 | $335 | $21 |
| Diclofenac | None | 13 | $279 | $21 |
| Atorvastatin | None | 20 | $274 | $14 |
| Propranolol Hcl Er | None | 15 | $237 | $16 |
| Sertraline | None | 12 | $187 | $16 |
| Trazodone | None | 12 | $120 | $10 |
| Pramipexole Dihydrochloride | None | 13 | $40 | $3 |
2020: 20 drugs
| Nuedexta | 16 | $19,755 | $1,235 |
| Memantine Hcl Er | 48 | $10,641 | $222 |
| Rivastigmine | 21 | $10,576 | $504 |
| Eliquis | 12 | $5,938 | $495 |
| Sumatriptan | 23 | $4,738 | $206 |
| Carbidopa-Levodopa | 50 | $3,929 | $79 |
| Pregabalin | 49 | $3,488 | $71 |
| Gabapentin | 75 | $2,419 | $32 |
| Memantine | 28 | $2,355 | $84 |
| Clonazepam | 21 | $1,250 | $60 |
| Zonisamide | 12 | $1,022 | $85 |
| Ropinirole | 19 | $743 | $39 |
| Lamotrigine | 13 | $687 | $53 |
| Rizatriptan | 16 | $682 | $43 |
| Topiramate | 17 | $495 | $29 |
| Donepezil | 46 | $471 | $10 |
| Diclofenac | 13 | $271 | $21 |
| Quetiapine | 13 | $121 | $9 |
| Alprazolam | 12 | $73 | $6 |
| Amlodipine Besylate | 15 | $32 | $2 |
2019: 13 drugs
| Rasagiline Mesylate | 16 | $17,263 | $1,079 |
| Memantine Hcl Er | 37 | $14,305 | $387 |
| Rivastigmine | 26 | $12,781 | $492 |
| Eliquis | 13 | $6,422 | $494 |
| Carbidopa-Levodopa | 32 | $4,163 | $130 |
| Memantine | 22 | $1,569 | $71 |
| Gabapentin | 86 | $1,221 | $14 |
| Donepezil | 50 | $973 | $19 |
| Quetiapine | 12 | $553 | $46 |
| Lamotrigine | 12 | $348 | $29 |
| Nortriptyline | 22 | $298 | $14 |
| Clonazepam | 14 | $148 | $11 |
| Ropinirole | 14 | $103 | $7 |
2018: 16 drugs
| Rasagiline Mesylate | 19 | $16,292 | $857 |
| Nuedexta | 14 | $15,232 | $1,088 |
| Rivastigmine | 23 | $12,488 | $543 |
| Memantine Hcl Er | 28 | $10,109 | $361 |
| Carbidopa-Levodopa | 57 | $3,065 | $54 |
| Memantine | 28 | $1,625 | $58 |
| Gabapentin | 74 | $1,303 | $18 |
| Levetiracetam | 32 | $1,137 | $36 |
| Donepezil | 86 | $1,110 | $13 |
| Primidone | 29 | $835 | $29 |
| Quetiapine | 47 | $748 | $16 |
| Lamotrigine | 30 | $505 | $17 |
| Levetiracetam Er | 11 | $458 | $42 |
| Clonazepam | 16 | $144 | $9 |
| Imipramine | 12 | $85 | $7 |
| Atorvastatin | 11 | $73 | $7 |
2017: 19 drugs
| Nuedexta | 31 | $23,433 | $756 |
| Rasagiline Mesylate | 33 | $21,641 | $656 |
| Azilect | 19 | $17,090 | $899 |
| Rivastigmine | 34 | $15,671 | $461 |
| Namenda Xr | 24 | $15,061 | $628 |
| Exelon | 11 | $15,025 | $1,366 |
| Donepezil | 136 | $2,548 | $19 |
| Carbidopa-Levodopa | 55 | $2,061 | $37 |
| Gabapentin | 98 | $1,188 | $12 |
| Levetiracetam | 36 | $1,141 | $32 |
| Primidone | 38 | $731 | $19 |
| Topiramate | 28 | $649 | $23 |
| Quetiapine | 28 | $402 | $14 |
| Tizanidine | 27 | $331 | $12 |
| Lamotrigine | 31 | $327 | $11 |
| Nortriptyline | 24 | $211 | $9 |
| Clopidogrel | 14 | $70 | $5 |
| Clonazepam | 13 | $54 | $4 |
| Imipramine | 12 | $48 | $4 |
2016: 19 drugs
| Azilect | 38 | $31,528 | $830 |
| Exelon | 23 | $12,020 | $523 |
| Namenda Xr | 31 | $11,666 | $376 |
| Gabapentin | 142 | $1,520 | $11 |
| Carbidopa-Levodopa | 51 | $1,384 | $27 |
| Donepezil | 112 | $1,276 | $11 |
| Lamotrigine | 43 | $1,022 | $24 |
| Levetiracetam | 45 | $844 | $19 |
| Primidone | 46 | $741 | $16 |
| Tizanidine | 37 | $386 | $10 |
| Ropinirole | 15 | $375 | $25 |
| Quetiapine | 29 | $304 | $10 |
| Clopidogrel | 14 | $278 | $20 |
| Verapamil | 14 | $265 | $19 |
| Topiramate | 28 | $227 | $8 |
| Clonazepam | 22 | $123 | $6 |
| Tramadol | 11 | $77 | $7 |
| Nortriptyline | 16 | $76 | $5 |
| Citalopram Hbr | 13 | $24 | $2 |
2015: 16 drugs
| Azilect | 20 | $13,571 | $679 |
| Exelon | 21 | $9,925 | $473 |
| Namenda Xr | 12 | $4,793 | $399 |
| Gabapentin | 127 | $1,912 | $15 |
| Carbidopa-Levodopa | 42 | $1,642 | $39 |
| Donepezil | 95 | $902 | $9 |
| Quetiapine | 24 | $882 | $37 |
| Lamotrigine | 31 | $867 | $28 |
| Levetiracetam | 30 | $807 | $27 |
| Primidone | 22 | $406 | $18 |
| Ropinirole | 22 | $386 | $18 |
| Tizanidine | 26 | $309 | $12 |
| Mirtazapine | 14 | $266 | $19 |
| Verapamil | 11 | $197 | $18 |
| Nortriptyline | 17 | $89 | $5 |
| Clonazepam | 16 | $65 | $4 |
2014: 17 drugs
| Azilect | 23 | $19,453 | $846 |
| Exelon | 31 | $10,409 | $336 |
| Mirapex Er | 11 | $5,278 | $480 |
| Namenda Xr | 11 | $3,202 | $291 |
| Carbidopa-Levodopa | 55 | $2,544 | $46 |
| Gabapentin | 167 | $2,489 | $15 |
| Levetiracetam | 38 | $1,019 | $27 |
| Tizanidine | 43 | $793 | $18 |
| Clopidogrel | 20 | $768 | $38 |
| Donepezil | 55 | $752 | $14 |
| Quetiapine | 22 | $543 | $25 |
| Primidone | 31 | $502 | $16 |
| Mirtazapine | 12 | $305 | $25 |
| Verapamil | 13 | $201 | $15 |
| Lamotrigine | 11 | $173 | $16 |
| Tramadol | 13 | $140 | $11 |
| Nortriptyline | 19 | $136 | $7 |
2013: 15 drugs
| Azilect | 33 | $24,005 | $727 |
| Exelon | 56 | $18,439 | $329 |
| Carbidopa-Levodopa | 46 | $2,661 | $58 |
| Gabapentin | 170 | $2,475 | $15 |
| Levetiracetam | 33 | $1,285 | $39 |
| Clopidogrel | 19 | $1,049 | $55 |
| Tizanidine | 60 | $1,024 | $17 |
| Donepezil | 36 | $1,014 | $28 |
| Carbidopa-Levodopa-Entacapone | 11 | $914 | $83 |
| Quetiapine | 23 | $812 | $35 |
| Primidone | 28 | $557 | $20 |
| Mirtazapine | 18 | $346 | $19 |
| Lamotrigine | 17 | $224 | $13 |
| Nortriptyline | 22 | $185 | $8 |
| Clonazepam | 11 | $38 | $3 |
Money from drug and device companies
$947 in 2025
| 2025 | 5 | 16 | None | $947 |
| 2024 | 2 | 2 | None | $154 |
| 2023 | 2 | 2 | None | $244 |
| 2022 | 5 | 7 | None | $618 |
| 2021 | 5 | 11 | None | $1,050 |
| 2020 | 2 | 2 | None | $133 |
| 2019 | 9 | 19 | None | $2,108 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lundbeck | Vyepti | $300 | 8 payments
|
| Alexion Pharmaceuticals | Ultomiris | $270 | 2 payments
|
| Janssen Biotech | None | $202 | 3 payments
|
| Lilly USA | Kisunla | $115 | 1 payment
|
| Abbvie | Botox | $60 | 2 payments
|
See all 16 published payments
| Abbvie | Meals · 2025-12-16 | Vyalev | $27 |
| Lundbeck | Meals · 2025-12-03 | Vyepti | $23 |
| Janssen Biotech | Meals · 2025-11-20 | None | $19 |
| Lundbeck | Meals · 2025-10-31 | Vyepti | $24 |
| Janssen Biotech | Meals · 2025-10-02 | None | $150 |
| Janssen Biotech | Meals · 2025-09-11 | None | $34 |
| Lundbeck | Meals · 2025-07-17 | Vyepti | $18 |
| Lundbeck | Meals · 2025-06-26 | Vyepti | $28 |
| Alexion Pharmaceuticals | Meals · 2025-05-29 | Ultomiris | $135 |
| Alexion Pharmaceuticals | Meals · 2025-05-29 | Ultomiris | $135 |
| Lundbeck | Meals · 2025-05-16 | Vyepti | $23 |
| Lilly USA | Meals · 2025-05-14 | Kisunla | $115 |
| Lundbeck | Meals · 2025-04-11 | Vyepti | $31 |
| Abbvie | Meals · 2025-03-25 | Botox | $33 |
| Lundbeck | Meals · 2025-02-06 | Vyepti | $29 |
| Lundbeck | Meals · 2025-01-16 | Vyepti | $125 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $154
| Lundbeck | Vyepti | $125 | 1 payment
|
| Abbvie | Botox | $29 | 1 payment
|
2023: $244
| SK Life Science | Xcopri | $125 | 1 payment
|
| Horizon Therapeutics plc | Uplizna | $119 | 1 payment
|
2022: $618
| Abbvie | Ubrelvy | $260 | 3 payments
|
| SK Life Science | Xcopri | $125 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $124 | 1 payment
|
| Horizon Therapeutics plc | Uplizna | $97 | 1 payment
|
| Impel Pharmaceuticals | Trudhesa | $12 | 1 payment
|
2021: $1,050
| AbbVie | Ubrelvy | $498 | 4 payments
|
| SK Life Science | Xcopri | $375 | 3 payments
|
| Genzyme | None | $122 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $30 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $25 | 1 payment
|
2020: $133
| Teva Pharmaceuticals USA | Ajovy | $120 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $13 | 1 payment
|
2019: $2,108
| Novartis Pharmaceuticals | Mayzent | $739 | 7 payments
|
| Teva Pharmaceuticals USA | Ajovy | $342 | 3 payments
|
| Lundbeck | Northera | $232 | 2 payments
|
| Genzyme | Aubagio | $200 | 2 payments
|
| Portola Pharmaceuticals | Andexxa | $125 | 1 payment
|
| Amgen | Aimovig | $125 | 1 payment
|
| Lilly USA | None | $123 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $121 | 1 payment
|
| Genentech USA | Ocrevus | $100 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417169491
- Licence
- CA A97089, IL 036-117540California A97089: Current · expires 2028-05-31Illinois 036117540: Not Renewed
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-05-04
- NPI last updated
- 2026-07-25
- NPI record certified
- 2026-07-25
This is when the NPI record was last certified, not a medical board exam.